Business
Scancell selects PharmaJet's Needle-free Systems
Scancell selects PharmaJet's Needle-free Systems.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8154I\n Scancell Holdings Plc\n 17 August 2021\n \n \n \n 17 August 2021\n \n Scancell Holdings plc\n (\"Scancell\" or the \"Company\")\n \n Scancell selects PharmaJet's clinically proven Needle-free Systems for COVID-19 vaccine trial\n \n Preclinical studies confirm that PharmaJet delivery of COVIDITY vaccines induces potent immune responses against both S and N antigens\n \n \n PharmaJet delivery improves both the patient and caregiver experience, reducing vaccine hesitancy\n \n \n \n Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces that it has selected the PharmaJet Needle-free Injection Systems to administer its two SARS-CoV-2 vaccine candidates, SCOV1 and SCOV2, in its COVIDITY Phase 1 clinical trial (COVIDITY-001). SCOV1 and SCOV2 will be administered either via an intradermal injection using the PharmaJet Tropis® Needle-free Injection System or via intramuscular delivery using the PharmaJet Stratis® system. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and World Health Organization (WHO) Performance, Quality and Safety (PQS) certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. The PharmaJet Systems are the first and only needle-free devices pre-qualified by the WHO.\n \n As announced on 29 July 2021, the Company's COVIDITY-001 study, including the use of the two PharmaJet injectors, has been approved by the South African regulatory authority. The COVIDITY programme is a collaboration between Scancell and scientists in the newly established Centre for Research on Global Virus Infections and the new Biodiscovery Institute at the University of Nottingham, and Nottingham Trent University and the programme has received funding from Innovate UK.\n \n Needle-free injectors use a narrow stream of fluid to penetrate the skin, delivering vaccines and other pharmaceuticals to the required tissue depth. Both the PharmaJet systems have been clinically proven with a wide range of vaccines, including the delivery of DNA products. These injection systems are easy to use, eliminate needlestick injuries and have the...